Don’t give pharmacists power over biosimilars: Australian Rheumatology Association

doctor makes "stop" gesture with hand - ama
The Australian Rheumatology Association has expressed concerns about risks to patient safety it says could follow from measures on biosimilars going through the Senate today as part of the wider Pharmaceutical Benefits Bill. “The proposed new powers will allow pharmacists to switch particular drugs at the pharmacy counter with the potential for patients to get

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy should be a health nexus: self-medication report
Next 6CPA, PBS amendment package passes Senate, welcomed by Guild